Abstract: Two preparations of dextran have been tried for prevention of venous thromboembolic disease, dextran-40 (average m. w. 40,000) and dextran-70 (average m.w. 70,000). Dextrans reduce platelet aggregation and lower blood viscosity. 1 Dextran may also reduce the peri-operative rise in the coagulation factors V and VIII. 2 However, in some tests dextrans increase platelet aggregation 3 and accelerate fibrin formation, 4 so that only clinical trial can show whether dextran reduces the incidence of either deep-vein thrombosis or of pulmonary embolism.
Publication Year: 1975
Publication Date: 1975-05-23
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot